Zacks Investment Research downgraded shares of Diplomat Pharmacy, Inc. (NYSE:DPLO) from a hold rating to a sell rating in a research report released on Thursday morning.
According to Zacks, “Diplomat Pharmacy, Inc. operates as an independent specialty pharmacy in the United States. It aids in the dispensing, delivery, dosing and reimbursement of clinically intensive and specialty drugs. The company focuses on medication management programs for people with complex chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, HIV, specialized infusion therapy and many other serious or long-term conditions. Diplomat Pharmacy, Inc. is headquartered in Flint, Michigan. “
A number of other equities analysts have also recently commented on DPLO. Mizuho dropped their price objective on shares of Diplomat Pharmacy from $39.00 to $17.00 and set a neutral rating for the company in a research note on Thursday, November 3rd. Leerink Swann lowered shares of Diplomat Pharmacy from an outperform rating to a market perform rating and lowered their target price for the stock from $35.00 to $18.00 in a report on Thursday, November 3rd. Avondale Partners lowered shares of Diplomat Pharmacy from an outperform rating to a market perform rating in a report on Thursday, November 3rd. Citigroup Inc. lowered shares of Diplomat Pharmacy to a market perform rating in a report on Thursday, November 3rd. Finally, Cowen and Company lowered their target price on shares of Diplomat Pharmacy from $37.00 to $18.00 and set a market perform rating for the company in a report on Thursday, November 3rd. Three investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and two have assigned a buy rating to the company’s stock. Diplomat Pharmacy currently has a consensus rating of Hold and a consensus target price of $25.56.
Shares of Diplomat Pharmacy (NYSE:DPLO) opened at 13.15 on Thursday. Diplomat Pharmacy has a one year low of $12.25 and a one year high of $38.94. The firm has a 50-day moving average of $13.21 and a 200-day moving average of $24.40. The stock has a market cap of $874.62 million, a PE ratio of 27.11 and a beta of 0.65.
Diplomat Pharmacy (NYSE:DPLO) last issued its quarterly earnings data on Wednesday, November 2nd. The company reported $0.21 EPS for the quarter, missing analysts’ consensus estimates of $0.24 by $0.03. Diplomat Pharmacy had a return on equity of 10.47% and a net margin of 0.77%. The business earned $1.18 billion during the quarter, compared to analysts’ expectations of $1.26 billion. During the same period in the previous year, the business earned $0.26 earnings per share. The business’s quarterly revenue was up 24.7% on a year-over-year basis. On average, equities research analysts expect that Diplomat Pharmacy will post $0.84 earnings per share for the current fiscal year.
Several large investors have recently bought and sold shares of DPLO. Dimensional Fund Advisors LP acquired a new stake in Diplomat Pharmacy during the second quarter valued at approximately $1,288,000. Teacher Retirement System of Texas raised its stake in Diplomat Pharmacy by 13.8% in the second quarter. Teacher Retirement System of Texas now owns 5,404 shares of the company’s stock valued at $189,000 after buying an additional 655 shares in the last quarter. Nationwide Fund Advisors raised its stake in Diplomat Pharmacy by 4.1% in the second quarter. Nationwide Fund Advisors now owns 59,815 shares of the company’s stock valued at $2,094,000 after buying an additional 2,348 shares in the last quarter. Ameriprise Financial Inc. raised its stake in Diplomat Pharmacy by 4.3% in the second quarter. Ameriprise Financial Inc. now owns 249,788 shares of the company’s stock valued at $8,744,000 after buying an additional 10,236 shares in the last quarter. Finally, Autus Asset Management LLC raised its stake in Diplomat Pharmacy by 11.5% in the second quarter. Autus Asset Management LLC now owns 51,360 shares of the company’s stock valued at $1,798,000 after buying an additional 5,310 shares in the last quarter. Institutional investors and hedge funds own 77.67% of the company’s stock.
Diplomat Pharmacy Company Profile
Diplomat Pharmacy, Inc operates a specialty pharmacy business, which stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. The Company’s primary focus is on medication management programs for individuals with chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialized infusion therapy, and various other serious and/or long-term conditions.
Get a free copy of the Zacks research report on Diplomat Pharmacy (DPLO)
For more information about research offerings from Zacks Investment Research, visit Zacks.com